A firm touting itself as «Britain’s first psychedelic healthcare fund» has launched with the intention to invest more than £10 million in psychedelic focused companies.
With much of the current investments occurring in the US and Canada, Neo Kuma aims to capitalize on the European psychedelic market.
As cofounder Sean McLintock stated, «As the medical benefits of psychedelics become more well-known and regulators steadily increase their embrace of these types of drugs, the industry is set for a boom. While much of the conversation on psychedelics is taking place in the US, Europe is the true hub of the burgeoning psychedelic healthcare sector».
Source: Psychedelic Invest
No comments:
Post a Comment